Kornimate/medical-research-clean huggingface dataset:
world mosquito program noumea - human sample component

Conditions: Arbovirus Infections

Summary: the dengue, zika and chikungunya arboviruses represent potentially severe infections to which the new caledonian population is exposed. in the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. however, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... the world mosquito program noumea project is based on the artificial colonization of the mosquito vector aedes aegypti by the endosymbiotic bacteria wolbachia, which reduces its ability to transmit arboviruses. the breeding of mosquitoes carrying the bacterium wolbachia in the laboratories of the institut pasteur of new caledonia requires the use of human blood samples for mosquito gorging. the objective of the research is to generate, maintain and amplify aedes aegypti caledonian lineages carrying the wolbachia bacteria for the planned insect release program in noumea.

the dengue, zika and chikungunya arboviruses represent potentially severe infections to which the new caledonian population is exposed. in the absence of specific treatment or vaccine, disease vector control remains the method of choice to limit their spread. however, the traditional methods of prevention and disease vector control must today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... the world mosquito program noumea project is based on the artificial colonization of the mosquito vector aedes aegypti by the endosymbiotic bacterium wolbachia, which reduces its ability to transmit arboviruses. the breeding of mosquitoes carrying the bacterium wolbachia in the laboratories of the institut pasteur of new caledonia requires the use of human blood samples for mosquito gorging. the objective of the research is to generate, maintain and amplify aedes aegypti caledonian lineages carrying the bacterium wolbachia for the planned insect release program in noumea. the establishment of wolbachia in aedes aegypti populations in noumea should lead to the reduction of active transmission of dengue, zika and chikungunya in the municipality.

Eligibility criteria:
inclusion criteria: * all adult hemochromatosis or polycythemia patients or healthy donors have given their written consent to participate in the study and for the collection of a blood sample. exclusion criteria: * participation refusal * minor person * positive result by reverse transcription polymerase chain reaction rt-pcr for arboviruses * invalid qualification of the blood donation

Keywords: arbovirus
vitamin c in thermal injury: the victory trial

Conditions: Shock; Thermal Burn

Summary: this study aims to show that giving high dose, intravenous vitamin c in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. in this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin c, while the other half of patients will receive placebo.

in certain disease states, such as those associated with severe burns and other critical illnesses, the relationship between nutrient deficiencies, altered immune status, and acquired infection has been recognized for many years. more than in any other injury, the inflammation and catabolism associated with severe burns can exacerbate nutrient deficiencies, thereby predisposing patients to impaired immune function and increased risk of developing infectious complications, organ dysfunction, and death. we aim to conduct a large-scale, multi-center randomized trial to evaluate the effect of high-dose (50mg/kg every 6 hours for 96 hours) intravenous vitamin c in addition to standard of care (soc) on 28-days composite outcome of persistent organ dysfunction (pod) and all-cause mortality compared to add-on placebo and soc. patients will be allocated to 2 groups, active or control: patients in the active group will receive intravenous vitamin c at 50mg/kg every 6 hrs for 96 hrs. patients in the control group will receive a similar amount of placebo (either d5w or saline) delivered in the same manner as the vitamin c. this study will be the first large international multi-centre trial examining the effects of high dose intravenous vitamin c in burn patients. it represents a unique collaboration of burn units worldwide that is coordinated by the clinical evaluation research unit, based in kingston ontario canada, a coordinating center that has demonstrated the ability to run multi-center trials and translate findings into practice.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * deep 2nd and/or 3rd degree burns requiring skin grafting * minimum burn size of ≥ 20% total body surface area (tbsa) exclusion criteria: * \>24 hours from admission to participating hospital to consent. * patients admitted to burn unit \>24 from injury or accident. * patients who are moribund (not expected to survive the next 72 hours). * pregnancy (pregnancy will be ruled out as part of standard of care) or lactating. * enrollment in another industry sponsored icu intervention study. * receiving high-dose iv vitamin c already (enteral or oral vitamin c is allowed). * known glucose-6-phosphate dehydrogenase (g6pd) deficiency. * recent history of kidney stones (within the last year). * concomitant use of hydroxycobalamin (vitamin b12) for suspected cyanide poisoning.
antibiotic duration in post-appendectomy abscess

Conditions: Complicated Appendicitis; Perforated Appendicitis

Summary: this is a randomized study of patients 2-17 years old who are diagnosed with perforated appendicitis and develop an abscess after laparoscopy that is subsequently drained. patients will be randomized to either receive an 8-day or a 4-day course of antibiotics. the aim of this study is to determine whether duration of antibiotic treatment at discharge demonstrates significant differences in clinical outcomes.

the central aim of this study is to determine whether duration of antibiotic treatment at discharge demonstrates significant differences in primary and secondary clinical outcomes. specifically, this research aims to determine whether the readmission rate and length of stay for pediatric patients diagnosed with perforated appendicitis who form a post-laparoscopic abscess that is treated with percutaneous drainage and are treated with a 8-day oral antibiotic regimen at discharge is significantly different from those treated with a fixed 4-day regimen at discharge. this study includes patients ages 2-17 years old who present with perforated appendicitis-as diagnosed at laparoscopy and photographed as either a hole or as feces in the abdomen-and who develop an abscess after laparoscopy that is treated with percutaneous drainage. all post-laparoscopic abscess patients will receive the standard of care for antibiotic therapy at phoenix children's hospital-iv ceftriaxone/metronidazole-until afebrile and tolerating food. all patients will be treated with the pch standard of care and receive in-patient treatment for abscess until afebrile. at discharge, study patients will be randomly assigned to either an 8-day ampicillin/clavulanate regimen or a 4-day ampicillin/clavulanate regimen. pediatric patients who are allergic to ampicillin will be excluded from the study. patients will be followed thirty days post discharge to assess clinical outcomes.

Eligibility criteria:
inclusion criteria: * age: 2 to 17 years of age * diagnosis of perforated appendicitis at laparoscopy * development of a post-appendectomy abscess that is treated with percutaneous drainage. exclusion criteria: * patients who are allergic to ampicillin
34mm cuff study for endovascular repair of abdominal aortic aneurysms

Conditions: Abdominal Aortic Aneurysm

Summary: study of anatomical fixation with a 34mm proximal extension

the 34mm proximal extension stent graft is intended to augment the primary 28mm infrarenal bifurcated stent graft to accommodate patient anatomy (neck diameters up to 32mm) and provide an effective seal to prevent/repair proximal type i endoleaks.

Eligibility criteria:
inclusion criteria: * 18 years old or older * informed consent understood and signed * will comply with protocol follow-up requirements * candidate for conventional open surgical repair * aneurysm outer diameter is one or more of the following: * greater than or equal to 4.0cm * greater than or equal to 3.0cm (saccular aneurysm) * greater than or equal to twice the normal aortic outer diameter * rapidly growing (greater than or equal to 5mm over 6 months) * proximal non-aneurysmal aortic neck fixation length greater than or equal to 1.5cm between the renal arteries and the aneurysm * non-aneurysmal proximal aortic neck inner diameter between 23 and 32mm * iliac artery internal diameter greater than or equal to 8 mm exclusion criteria: * life expectancy \<2 years * participating in another clinical study * pregnant or lactating women * acutely ruptured/leaking aneurysm * traumatic vascular injury * other medical or psychiatric problems * contraindication to non-ionic contrast media or anticoagulants * coagulopathy or bleeding disorder * active systemic or localized groin infection * indispensable inferior mesenteric artery * connective tissue disease (e.g., marfan's syndrome) * creatinine level \>1.7 mg/dl * renal transplant patient * proximal attachment site \>60º angle to the aneurysm body * iliac arteries \>90º angle * \<1.5 cm of non-aneurysmal common iliac artery above the iliac bifurcation on both sides \[one internal iliac artery is required to remain patent\] * thrombus \>30% at implantation site

Keywords: powerlink 34mm abdominal aortic aneurysm evar
diagnosis/pathophysiology of glucocorticoid remediable aldosteronism hypertension

Conditions: Cardiovascular Diseases; Hypertension; Heart Diseases

Summary: to identify and study a large cohort of glucocorticoid remediable aldosteronism (gra) patients.

design narrative: the spectrum of the severity and the natural history of the disorder was characterized. modifying environmental and genetic factors important in regulation of blood pressure were determined. also, renal physiology was studied in gra patients to determine how these patients escaped hypokalemia in spite of mineralocorticoid excess. there were four specific aims including: 1) to determine the natural history and prevalence of gra in various hypertensive populations, 2) to characterize the magnitude of effect imparted on blood pressure by inheritance of gra and the sources of variation in phenotype expression of the hypertension, 3) to investigate the renal and hormonal mechanisms regulating potassium conservation and loss in gra, and 4) to characterize the disequilibrium of gra with irish and scottish descent and specific alleles of the aldosterone synthase gene. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
study of taxane/carboplatin +/- cetuximab as first-line treatment for patients with advanced/metastatic non-small cell lung cancer

Conditions: Non-Small-Cell Lung Carcinoma

Summary: the primary purpose of this clinical research study is to learn if patients treated with the combination of taxane/carboplatin plus cetuximab (c/t/c) have a longer progression-free survival than patients treated with taxane/carboplatin (t/c) alone. the safety of this treatment will also be studied.


Eligibility criteria:
inclusion criteria: * must have advanced or metastatic non-small cell lung cancer that has not been previously treated with any chemotherapy. * tumor/disease lesions that can be measured bidimensionally. * must be able to carry-out work of light or sedentary nature (e.g. light house work, office work). * adequate recovery from recent surgery or radiation therapy. * must be at least 4 weeks from last major surgery or prior treatment with an investigational agent. at least 12 weeks from any radiation therapy to chest. * accessible for treatment, follow-up and required visits at a participating center(s). exclusion criteria: * prior chemotherapy or adjuvant chemotherapy for the treatment of lung cancer. * prior treatment with cetuximab or other epidermal growth factor (egfr)-targeted therapy. * prior severe infusion reaction to antibody therapy. * concurrent malignancy (previous malignancy without evidence of disease for 5 years will be allowed to enter trial). * concurrent chemotherapy or therapy with another investigational agent not indicated in the protocol. * serious uncontrolled medical disorders that would impair the ability to receive therapy. * history of myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure. * symptomatic or uncontrolled metastases in the central nervous system. subjects receiving a glucocorticoid for central nervous system (cns) metastases are not eligible, but those receiving an anticonvulsant are eligible. * peripheral neuropathy \>= grade 2 (common toxicity criteria adverse event \[ctcae\] version 3.0). * inadequate hematologic and/or liver and/or kidney function. * sexually active and fertile individuals or partners of these individuals who are unwilling or unable to use an acceptable method of birth control for entire trial and up to 4 weeks after the study. * women who are pregnant or breastfeeding. * women with a positive pregnancy test on enrollment prior to study drug administration. * altered mental status or psychiatric condition that prohibits understanding or rendering of consent.

Keywords: non-small cell lung cancer
gi symptoms and sleep disturbances in patients with quiescent crohns disease

Conditions: Crohn's Disease; Inflammatory Bowel Disease; Sleep Disturbances

Summary: in this study we would like to clarify the effect of long lasting crohn's disease on motility of the gastrointestinal system in patient and the effect regarding sleep disturbances. this will be done with a newly developed 3d-motility-and-transit-detector (motilis medica, schweiz) and the well known polysomnographic equipment. our hypothesises are: patients with ileocoecal and/or colonic cd in remission and gastrointestinal symptoms have abnormal colonic transit (primary endpoint). 1. patients with ileocoecal and/or colonic cd in remission and gastrointestinal symptoms have abnormal gastric emptying and small intestinal transit (secondary endpoints). 2. total and segmental transit times found in patients with cd will be compared with corresponding transit times in healthy volunteers found in a previous study. 3. patients with ileocoecal and/or colonic cd in remission have abnormal sleep patterns. 4. nocturnal basic colonic activity, have changed in patients with ileocoecal and/or colonic cd in remission and sleep disturbances.


Eligibility criteria:
inclusion criteria: * patients with cd based on accepted endoscopic and histological criteria (according to ecco guidelines (17) ) * age ≥18 years * a minimum disease duration of five years * remission defined by faecal calprotectin \< 100 and crp level within normal values for a minimum of 1 month * baseline values: * crp normal * faecal calprotectin \< 100 * ileocoecal and/or colic localization of disease (montreal phenotype classification) * one or more ibs-like-symptoms (abdominal pain and discomfort, diarrhea, constipation) exclusion criteria: * stricturizing cd * obvious stenotic symptoms * previous major gastrointestinal surgery * diagnosis of other gastrointestinal diseases affecting motility (ex. coeliac disease) * medication altering gastrointestinal motility * hepatobiliary disease (psc) * diabetes mellitus * metabolic disorder * bacterial overgrowth (hydrogen breath test) * planned mr scan in the four weeks following capsule intake (safety precaution) * abdominal diameter \> 140 cm * implanted electronic devices (pacemaker, icd, etc.) * diagnosed sleep disorder * pregnancy and breast feeding

Keywords: gastrointestinal motility motility tracking system (mts) transit time sleep pattern
lenalidomide and low dose dexamethasone versus bortezomib, lenalidomide and low dose dexamethasone for induction, in patients with previously untreated multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a randomized phase iii trial of cc-5013 (lenalidomide, nsc-703813) and low dose dexamethasone (lld) versus bortezomib (ps-341, nsc-681239), lenalidomide and low dose dexamethasone (blld) for induction, in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant.


Eligibility criteria:
1. patients must have newly diagnosed multiple myeloma 2. patients must have received no prior chemotherapy for this disease. patients must have received no prior radiotherapy to a large area of the pelvis (more than half of the pelvis). prior steroid treatment is allowed provided treatment was not more than 2 weeks in duration. patients must not have received any prior treatment with bortezomib or lenalidomide. 3. patients must be ≥ 18 years of age at the time of registration. 4. patients must have a zubrod performance status (ps) of 0 - 3 5. patients must have adequate marrow function as defined herein: 6. platelet count ≥ 80 x 103/mcl, 7. anc ≥ 1 x 103/mcl, and hemoglobin (including patients who have been either transfused or treated with epo) ≥ 9 g/dl. 8. institutions must submit a local cytogenetics report and fish analysis report 9. patients with pathologic fractures, pneumonia at diagnosis or symptomatic hyperviscosity. 10. patients must have a calculated or measured creatinine clearance \> 30 cc/min. 11. patients must not have uncontrolled, active infection requiring intravenous antibiotics 12. patients must not have any psychiatric illness 13. patients must not be hepatitis b, hepatitis c or hiv positive 14. patients must not have a history of cerebral vascular accident with persistent neurologic deficits. 15. patients must be able to take aspirin 325 mg daily 16. females of childbearing potential (fcbp) must have a negative serum or urine pregnancy test 17. no prior malignancy is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for five years. 18. patients must be offered participation in gep molecular studies for the evaluation of genetic polymorphisms.

Keywords: untreated without intent for immediate autologous stem cell transplant
machine learning assisted differentiation of low acuity patients at dispatch

Conditions: Emergencies

Summary: background: at emergency medical dispatch (emd) centers, resource constrained situations (rcs) where there are more callers requiring an ambulance than there are available ambulances are common. at the emd centers in uppsala and västmanland, patients experiencing these situations are typically assigned a low-priority response, are often elderly, and have non-specific symptoms. machine learning techniques offer a promising but largely untested approach to assessing risks among these patients. objectives: to establish whether the provision of machine learning-based risk scores improves the ability of dispatchers to identify patients at high risk for deterioration in rcs. design: multi-centre, parallel-grouped, randomized, analyst-blinded trial. population: adult patients contacting the national emergency line (112), assessed by a dispatch nurse in uppsala or västmanland as requiring a low-priority ambulance response, and experiencing an rcs. outcomes: primary: 1. proportion of rcs where the first available ambulance was dispatched to the patient with the highest national early warning score (news) score secondary: * difference in composite risk score consisting of ambulance interventions, emergent transport, hospital admission, intensive care, and mortality between patients receiving immediate vs. delayed ambulance response during rcs. * difference in news between patients receiving immediate vs. delayed ambulance response during rcs. intervention: a machine learning model will estimate the risk associated with each patient involved in the rcs, and propose a patient to receive the available ambulance. in the intervention arm only, the assessment will be displayed in a user interface integrated into the dispatching system. trial size: 1500 rcs each consisting of multiple patients randomized 1:1 to control and intervention arms


Eligibility criteria:
inclusion criteria: * identification of a resource constrained situation by ambulance director (i.e., 2 or more patients awaiting an ambulance response) * assigned priority 2a or 2b (low-priority ambulance response) by dispatch nurse call-taker * valid swedish personal identification number collected at dispatch * age \>= 18 years exclusion criteria: * relevant calls received more than 30 minutes apart * logistical factors (eg. the patients' geographical locations) affect the ambulance assignment decision * on scene risk factors (eg. a patient is outdoors and risks hypothermia) or risk mitigators (eg. healthcare staff already on-scene with a patient) affect the ambulance assignment decision
lower extremity pressure splints in hp

Conditions: Hemiplegia; Lower Extremity Dysfunction; Stroke Rehabilitation

Summary: hemiplegia (weakness or paralysis on one side of the body) often impacts the lower extremities, making it challenging for patients to walk or move their legs effectively. this study aims to explore the effects of pressure splints on the lower extremity movement and function in individuals who have experienced a stroke and suffer from hemiplegia. pressure splints are specialized devices designed to support and enhance muscle function by applying gentle pressure to the affected limbs. participants in this study will be randomly assigned to one of two groups: the splint group (sg) or the control group (cg). the duration of the intervention will be six weeks. during this period, all the participants will receive neurodevelopmental therapy. in the sg exercises will be done with the help of the lower extremity pressure splints while participants in the cg will join the exercises without any splint. this study is significant as it may lead to the development of new methods to enhance recovery for stroke patients and offer better rehabilitation options.


Eligibility criteria:
inclusion criteria: * having hemiplegia because of stroke * time since stroke: 1 month to 1 year * ability to participate (a score of \>24 on the mini-mental state examination). * being voluntary * age between 50-80 exclusion criteria: severe cognitive impairment other neurological disorders severe comorbidities or spasticity on lower extremity contraindications to exercise recurrent stroke

Keywords: stroke rehabilitation gait johnstone splint motor recovery